Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia

Chimeric antigen receptor (CAR)-modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS,...

詳細記述

保存先:
書誌詳細
出版年:Cancer Discov
主要な著者: Teachey, David T., Lacey, Simon F., Shaw, Pamela A., Melenhorst, J. Joseph, Maude, Shannon L., Frey, Noelle, Pequignot, Edward, Gonzalez, Vanessa E., Chen, Fang, Finklestein, Jeffrey, Barrett, David M., Weiss, Scott L., Fitzgerald, Julie C., Berg, Robert A., Aplenc, Richard, Callahan, Colleen, Rheingold, Susan R., Zheng, Zhaohui, Rose-John, Stefan, White, Jason C., Nazimuddin, Farzana, Wertheim, Gerald, Levine, Bruce L., June, Carl H., Porter, David L., Grupp, Stephan A.
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448406/
https://ncbi.nlm.nih.gov/pubmed/27076371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0040
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料